| Ms Lou Ann Jones, MS, CCC-A | |
|
333 Waller Ave Ste 300, Lexington, KY 40504-2927 | |
| (859) 252-3170 | |
| (859) 225-7155 |
| Full Name | Ms Lou Ann Jones |
|---|---|
| Gender | Female |
| Speciality | Hearing Instrument Specialist |
| Location | 333 Waller Ave Ste 300, Lexington, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700922978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 111 (Kentucky) | Primary |
| 237700000X | Hearing Instrument Specialist | 353 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lou Ann Jones, MS, CCC-A 333 Waller Ave Ste 300, Lexington, KY 40504-2927 Ph: (859) 252-3170 | Ms Lou Ann Jones, MS, CCC-A 333 Waller Ave Ste 300, Lexington, KY 40504-2927 Ph: (859) 252-3170 |
News Archive
As the world grapples with the COVID-19 pandemic, new questions arise as to the risk posed by the virus to different patient populations, including the elderly and those with underlying disease. A new study published on the preprint server medRxiv* in May 2020 deals with the risk of COVID-19 in the subgroup of patients with cancer.
Birthweight and gestational age are risk factors for retinopathy of prematurity and should be considered when screening infants for the condition, a study by Turkish researchers shows.
The AZTI-Tecnalia technological centre, in a project undertaken by the Tecnolat and Llet de Catalunya dairy product companies within the FUTURAL project, has verified that, as an alternative to the traditional heat treatment for decontamination of a number of dairy products, high pressure technology is highly recommendable. In fact, according to a press release from Tecnolat, the results, especially with ready-to-eat fruit products and in the inactivation of moulds and yeasts in other dairy products, "were highly positive and promising".
For the first time gene therapy for cystic fibrosis has shown a significant benefit in lung function compared with placebo, in a phase 2 randomised trial published in The Lancet Respiratory Medicine journal. The technique replaces the defective gene response for cystic fibrosis by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells.
Despite the obvious difference between a chihuahua and a doberman, the human brain effortlessly categorises them both as dogs, a feat that is thus far beyond the abilities of artificial intelligence.
› Verified 2 days ago